FDA Approved: NIVESTYM — Original Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

The FDA approved NIVESTYM (filgrastim-aafi) from Pfizer as a biosimilar to filgrastim for reducing duration of neutropenia and infection risk in cancer patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neutropenia

Drugs mentioned

• NIVESTYM (FILGRASTIM-AAFI)

Snippet

ORIG AP for NIVESTYM (FILGRASTIM-AAFI)